Company Encyclopedia
View More
name
Inmune Bio
INMB.US
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs.
1.946 T
INMB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking146/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-155.77%E
    • Profit Margin-99774.00%E
    • Gross Margin0.00%E
  • Growth ScoreC
    • Revenue YoY19.05%B
    • Net Profit YoY-20.87%D
    • Total Assets YoY-36.80%E
    • Net Assets YoY-34.38%E
  • Cash ScoreC
    • Cash Flow Margin-0.10%D
    • OCF YoY19.05%B
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio23.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    INmune Bio Inc. Updates Executive Compensation Agreements

    INmune Bio Inc. has updated the employment agreements for its President and CEO, David J. Moss, and CFO, Cory Ellspermann. Moss's salary is now $454,000 annually with 750,000 stock options, while Ellspermann's salary is $240,000 annually. These changes correct previous errors in their agreements from November 2025.

    Reuters·
    US
    INMB
    +6.82%
    Reuters·
    US
    INMB
    +6.82%

    INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease

    INmune Bio Inc. announced positive Phase 2 neuroimaging data for XPro1595 in early Alzheimer's disease patients with high neuroinflammation. The results, showing reduced cortical disarray, will be presented at the CTAD conference in December 2025. This AI-generated news brief is for informational purposes only and not financial advice.

    Reuters·
    US
    INMB
    +6.82%
    Reuters·
    US
    INMB
    +6.82%

    INmune Bio Unveils Phase 2 Alzheimer's Trial Results at CTAD Conference

    INmune Bio Inc. will present Phase 2 trial results of XPro1595 for early Alzheimer's at the CTAD conference in San Diego, December 1-4, 2025. The first presentation will discuss the MINDFuL trial results, and the second will validate the EMACC through blood-based biomarkers. This announcement was originally published via EDGAR by INmune Bio.

    Reuters·
    US
    INMB
    +6.82%
    Reuters·
    US
    INMB
    +6.82%

    Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion

    Inmune Bio Inc. has completed Phase 2 trials for its immunotherapy programs, CORDStrom and XPro, targeting rare pediatric diseases and Alzheimer’s. The company plans regulatory filings and Phase 3 trials, aiming for market entry. Analysts rate INMB stock as a Buy with an $8.00 price target, but Spark's AI Analyst gives it a Neutral rating due to financial challenges and mixed technical signals. Inmune Bio focuses on next-generation immunotherapies and is listed on NASDAQ under the ticker INMB, with a current market cap of $43.33M.

    Tip Ranks·
    US
    INMB
    +6.82%
    Tip Ranks·
    US
    INMB
    +6.82%

    Inmune Bio (INMB) Gets a Hold from BTIG

    According to TipRanks, Shrader is a 3-star analyst with an average return of 2.6% and a 38.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, Gain Therapeutics, and Harrow Health. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inmune Bio with a $8.00 average price target.

    Tip Ranks·
    US
    INMB
    +6.82%
    Tip Ranks·
    US
    INMB
    +6.82%
    © 2025 Longbridge｜Disclaimer